← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS › PROPULSIVES › Propulsives
cisapride
A03FA02
Forms & Strengths
- Oral Tablet: 5 mg
- Oral Tablet: 10 mg
- Oral Suspension: 1 mg/mL
Adult Dosing
- GERD: 5 to 10 mg orally 3 to 4 times daily, 15 minutes before meals and at bedtime
- Maximum daily dose: 40 mg/day
Pediatric Dosing
- Neonates, Infants, and Children: 0.15 to 0.3 mg/kg/dose administered 3 to 4 times daily
- Maximum daily dose: 0.8 mg/kg/day or 20 mg/day
Indications
- Nocturnal heartburn due to gastroesophageal reflux disease (GERD)
- Available primarily through restricted access/compassionate use programs due to severe cardiac risks
Mechanism of Action
- Serotonin 5-HT4 receptor agonist
- Stimulates release of acetylcholine in the myenteric plexus of the GI tract
- Enhances lower esophageal sphincter tone and accelerates gastric emptying and colonic transit
Contraindications
- Known hypersensitivity to cisapride
- QT prolongation or congenital long QT syndrome
- Concomitant use of CYP3A4 inhibitors (e.g., azole antifungals, macrolide antibiotics, HIV protease inhibitors)
- Concomitant use of drugs known to prolong the QT interval (e.g., certain antiarrhythmics, tricyclic antidepressants, antipsychotics)
- Electrolyte disturbances (hypokalemia, hypomagnesemia)
Adverse Reactions
- QT prolongation, Torsades de Pointes, ventricular arrhythmias, sudden death
- Diarrhea, abdominal pain, nausea, dyspepsia
- Headache, dizziness
- Rhinitis, sinusitis, upper respiratory tract infection
Drug Interactions
- CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, erythromycin): significantly increase cisapride plasma concentrations, precipitating fatal arrhythmias
- QT-prolonging agents: additive risk of severe cardiac arrhythmias
- Anticholinergic agents: may antagonize the gastrointestinal motility effects of cisapride
- Accelerated gastric emptying may alter the absorption of concomitantly administered oral medications
Curated Content: Needs Vetting Before Put to Clinical Use